摘要
粘着斑激酶 (FAK) 是一种非受体酪氨酸激酶,参与细胞增殖、存活、迁移和侵袭过程。由于其在多种癌症类型中的过度表达和/或激活,它已成为治疗人类转移性癌症的有希望的治疗靶点。由于 FAK 因其在癌症中的转录和翻译水平的过度表达而成为潜在的癌症靶点,因此在过去几年中发现了具有多样化支架的不同类型的 FAK 抑制剂。本文综述了近期发现的小分子FAK抑制剂的研究进展。主要的努力集中在小分子FAK抑制剂的合理设计和合成上,并且还讨论了它们的构效关系(SAR)分析。其中,虽然 I 型抑制剂仍然是主要焦点,但 II 型抑制剂和新型变构 FAK 抑制剂(III 型抑制剂)已被开发以提高效力和选择性。同时,还发现了新的策略,例如使用蛋白质-蛋白质相互作用的抑制剂靶向 FAK。最后,提供了一些关于 FAK 抑制剂作为抗癌疗法的未来发展的见解和观点。
关键词: 抗癌疗法、癌症靶点、药物设计、粘着斑激酶 (FAK)、小分子 FAK 抑制剂、构效关系 (SAR) 分析。
Current Medicinal Chemistry
Title:Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics
Volume: 28 Issue: 34
关键词: 抗癌疗法、癌症靶点、药物设计、粘着斑激酶 (FAK)、小分子 FAK 抑制剂、构效关系 (SAR) 分析。
摘要: Focal Adhesion Kinase (FAK) is a non-receptor tyrosine kinase involved in the process of cell proliferation, survival, migration, and invasion. It has become a promising therapeutic target for the treatment of human metastatic cancers due to its overexpression and/or activation in multiple cancer types. Since FAK is emerging as a potential cancer target because of its overexpression at both the transcriptional and translational level in cancer, different types of FAK inhibitors with diversified scaffolds have been discovered in the past few years. In this review, the progress of recently discovered small molecule FAK inhibitors was summarized. Major efforts have been focused on the rational design and synthesis of small molecule FAK inhibitors, and their structure-activity relationship (SAR) analysis wasalso discussed. Among them, while type I inhibitors remain as the major focuses, type II inhibitors and novel allosteric FAK inhibitors (type III inhibitors) have been developed to improve both potency and selectivity. Meanwhile, novel strategies, such as targeting FAK using inhibitors of protein-protein interactions, were also discovered. Lastly, some insights and perspectives on the future development of FAK inhibitors as anticancer therapeutics have been provided.
Export Options
About this article
Cite this article as:
Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics, Current Medicinal Chemistry 2021; 28 (34) . https://dx.doi.org/10.2174/0929867328666210331143827
DOI https://dx.doi.org/10.2174/0929867328666210331143827 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Development of Ataxia Telangiectasia Mutated Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design Redox Environment and its Meaning for Breast Cancer Cells Fate
Current Cancer Drug Targets Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets Adenovirus-based Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization
Current Cancer Drug Targets New N’-Arylidene-2-[(4-Nitrophenyl)Piperazın-1-yl]Acetohydrazide Derivatives: Synthesis and Anticancer Activity Investigation
Letters in Drug Design & Discovery Editorial [Hot Topic: Development of Drugs Interfering with Apoptosis (Executive Guest Editor: Sebastiano Cavallaro)]
Current Pharmaceutical Design Vitamins for Cancer Prevention and Treatment: An Insight
Current Molecular Medicine Targeting ErbB Receptors in High-Grade Glioma
Current Pharmaceutical Design Evaluation of Venom as a Promising Tool for Drug Discovery: Focusing on Neurological Disorders
Venoms and Toxins Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets The Role of the Endoplasmic Reticulum in the Accumulation of β-Amyloid Peptide in Alzheimers Disease
Current Molecular Medicine The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment
Current Drug Targets Editorial (Thematic Issue: New Therapeutic Approaches for the Treatment of Glioblastoma)
Current Cancer Drug Targets Targeting the Brain: Advances in Drug Delivery
Current Pharmaceutical Biotechnology Pleiotropic Effects of Tocotrienols and Quercetin on Cellular Senescence: Introducing the Perspective of Senolytic Effects of Phytochemicals
Current Drug Targets Protein Degradation Pathways after Brain Ischemia
Current Drug Targets